US Patent 7674779 RNAi modulation of MLL-AF4 and uses thereof
Patent 7674779 was granted and assigned to Alnylam Pharmaceuticals on March, 2010 by the United States Patent and Trademark Office.
All edits
Edits on 30 Oct, 2023
Golden AI
Edits made to:
Article (+218 characters)
Article
Patent abstract
The invention relates to compositions and methods for modulating the expression of the MLL-AF4 fusion gene, and more particularly to the downregulation of MLL-AF4 by chemically modified oligonucleotides.
Edits on 21 May, 2023
Golden AI
Edits made to:
Infobox (-1 properties)
Infobox
Official Website
Edits on 19 May, 2023
Golden AI
Edits made to:
Infobox (+1/-1 properties)
US Patent 07674779 RNAi modulation of MLL-AF4 and uses thereof US Patent 7674779 RNAi modulation of MLL-AF4 and uses thereof
Infobox
Patent Number
0767477900
Patent Number
767477900
Edits on 26 Mar, 2023
Golden AI
Infobox
Is a
Current Assignee
Patent Jurisdiction
Patent Number
076747790
Date of Patent
March 9, 2010
0Patent Application Number
120388080
Date Filed
February 27, 2008
0Official Website
Patent Primary Examiner
Edits on 22 Sep, 2022
Golden AI
Infobox
Is a
Current Assignee
Patent Jurisdiction
Patent Number
076747790
Date of Patent
March 9, 2010
0Patent Application Number
120388080
Date Filed
February 27, 2008
0Official Website
Patent Primary Examiner
Edits on 18 Jun, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Website URL
Edits on 4 Dec, 2021
Golden AI
Edits made to:
Infobox (+8 properties)
US Patent 07674779 RNAi modulation of MLL-AF4 and uses thereof
Infobox
Is a
Current assignee
Patent jurisdiction
Patent number
07674779
Date of patent
March 9, 2010
Patent application number
12038808
Date Filed
February 27, 2008
Patent primary examiner
Find more entities like US Patent 7674779 RNAi modulation of MLL-AF4 and uses thereof
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
By using this site, you agree to our Terms of Service.